Fig 1: Protein expression of KLK6, VEGF, and MMP9 in various gastric cancer and normal gastric epithelial cells.KLK6 = kallikrein 6; VEGF = vascular endothelial growth factor; MMP9 = matrix metallopeptidase 9.
Fig 2: (A) qPCR and western blot analyses of KLK6, VEGF, and MMP9 expression in gastric cancer and adjacent normal tissues. (B) Immunohistochemical staining of KLK6, VEGF, and MMP9 in gastric cancer and adjacent normal tissues. The a, c, and e are tumor tissues; b, d, and f are normal tissues. (C) Kaplan–Meier curves suggesting that KLK6- patients had a significantly better chance of survival than KLK6+ patients. The ?2 and P-values are indicated in the plot.qPCR = quantitative polymerase chain reaction; KLK6 = kallikrein 6; VEGF = vascular endothelial growth factor; MMP9 = matrix metallopeptidase 9; mRNA = messenger RNA.*Indicated value means statistical significance.
Fig 3: (A) Western blot analysis of KLK6 and VEGF levels in KLK6high and KLK6low SGC-7901 cells. (B) The MTT assay was conducted to assess cell viability of KLK6high and KLK6low cells over a duration of 72 hours. (C) Colony formation assay was performed to compare the ability of KLK6high and KLK6low cells to form colonies. The number of colonies was then quantified.KLK6 = kallikrein 6; VEGF = vascular endothelial growth factor; MTT = methyl thiazolyl tetrazolium; KLK6high = kallikrein 6-high; KLK6low = kallikrein 6-low.*Indicated value means statistical significance.
Supplier Page from Abcam for Anti-Kallikrein 6 antibody - C-terminal